Survivorship After HNC: A Randomized Controlled Trial Evaluating Patient Care and Adherence to Follow-up

Official title

Survivorship After Head and Neck Cancer: A Randomized Controlled Trial Evaluating Patient Care and Adherence to Follow-up

Overview

Treatment summary and survivorship care plans (TSSPs) are poorly studied in Head and Neck Cancer (HNC) patients, and given the high frequency of unmet needs, this patient population has potentially the most to benefit from the implementation of TSSPs. A preliminary feasibility randomized control trial (RCT) at London Regional Cancer Program (LRCP) of 18 patients with HNC evaluating the implementation of TSSPs, found that patients assigned to the intervention group had a 15% higher rate of physician implementation of survivorship care needs compared to the usual care group (40% versus 25%, respectively). Results of the pilot study indicated that successful execution of TSSPs and counselling sessions for HNC patients is feasible. In follow up to the initial feasibility trial, the present investigation seeks to execute a large-scale randomized controlled trial. Three hundred and four patients who were treated at the London Regional Cancer Program (LRCP) for HNC will be randomly assigned to either usual care or a survivorship care plan (TSSP) intervention (90 patients in each arm). The intervention will consist of the delivery of a TSSP and a motivational interviewing counseling session with a clinical nurse specialist tailored to the needs of this vulnerable cancer population. The primary objective of the study is to evaluate the delivery of a TSSP during a one-on-one motivational interviewing counselling session with HNC survivors to determine whether the intervention results in improved implementation of recommendations for HNC survivors compared to usual care. Secondary study objectives will evaluate quality of life and satisfaction with care at 12 months post-intervention between the usual care and intervention group. Primary care providers of patients assigned to the intervention group will also be surveyed on the utility of the TSSP.

Detailed description

This study is a longitudinal randomized controlled trial. Patients will be randomly assigned to either usual treatment or the intervention (MI counselling session). Data will be collected at four time points: baseline (3-6 months post-treatment for HNC), and 3-, 6- and 12- months post-baseline visit. 180 patients with curable stage I-IV head and neck mucosal cancer (HNC) will be recruited to the study (90 per arm).

The intervention will consist of a survivorship care nurse motivational interviewing counseling session coupled with the provision of individualized TSSPs to patients and their health care providers.

The primary outcome will be physician implementation of survivorship care recommendations over the course of 12 months post-intervention assessed by quarterly patient surveys. Secondary outcomes will include adherence to recommended follow-up schedules, quality of life using validated measures, patient satisfaction with care, patient feedback on the utility of the TSSP and counselling session and physician feedback on the utility of the TSSP.

Interventions

• Other Motivational interviewing counselling session
  Individually tailored treatment summary and survivorship care plan provided within a 1-hour 1 hour counseling session with a clinical nurse specialist

Primary outcome measures

• Physician implementation of survivorship care recommendations [Time frame: 12 months]

Secondary outcome measures (4)

• Satisfaction with Care and Information Scale [Time frame: Baseline, 3, 6, and 12 months post-intervention]
• M.D. Anderson Symptom Inventory, Head and Neck Module (MDASI-HN) [Time frame: Baseline, 3, 6, and 12 months post-intervention]
• Patient Satisfaction with TSSP and Counselling SessionB [Time frame: Baseline]
• Physician Satisfaction with TSSP [Time frame: Baseline]

Eligibility criteria

Patient Participants

Inclusion criteria

• Age 18 years or older
• Willing to provide informed consent
• Diagnosis of stage I-IVA head and neck mucosal cancer (larynx, hypopharynx, oral cavity, oropharynx, nasopharynx)
• Last definitive treatment (surgery, chemotherapy, radiotherapy) between 3 and 6 months prior to enrollment
• English speaking, reading and writing

Exclusion criteria

• Second concurrent non-cutaneous malignancy
• Metastatic disease
• Clinically apparent cognitive impairment
• Suspected residual disease after treatment completion

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Supportive care

Study locations

Canada · 1 center

• Victoria Hospital, London Health Sciences Centre — London

Publications

• Tran B, Dzioba A, Baker J, Mutsaers A, Nichols AC, Mendez A, Goodman CD, Palma DA, Winquist E, Irwin JD, Fung K, Stewart P, Lang P, Correa RJM, Kuruvilla S, Mitchell S, Phillips T, MacNeil SD. The SHARE study - Survivorship After Head and Neck Cancer: evaluating patient care and adherence to follow up in Ontario, Canada: study protocol for a randomized controlled trial. Trials. 2025 Dec 13;27(1):4 PMID 41390453

Identifiers

NCT: NCT06127784 · 123657

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗